J&J buys Aragon’s prostate cancer arm

Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.

Related Content

Genentech to buy breast cancer specialist Seragon

2 July 2014 Business

news image

$1.7bn deal for hormone receptor-destroying drug pipeline

Riding new waves

6 January 2015 Business

news image

Pharmaceutical industry roundup of 2014

Most Commented

Antimony recovery lights up lamp waste recycling

2 October 2015 Research

news image

Green method produces fertiliser as a byproduct

Environmentally-friendly quantum dots make their mark

5 October 2015 Research

news image

Indium phosphide nanoparticles offer non-toxic alternative to cadium for richer, more colourful display screens